SHR-1701: Clinical Trials

3 trials of SHR-1701, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated, 1 unknown. 3 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 33Terminated 2, Unknown 1
Phase 21Terminated 1

Follow SHR-1701: new trials by email Literature Review of SHR-1701 trials Research Report on SHR-1701

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer
SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102, SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102, Placebo + paclitaxel + cisplatin/carboplatin ± BP102 - Cervical Cancer
Phase 3TerminatedSuzhou Suncadia Biopharmaceuticals Co., Ltd.312022-02-262025-04-15
Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer
SHR-1701 injection, Placebo - Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer
Phase 2 / Phase 3TerminatedSuzhou Suncadia Biopharmaceuticals Co., Ltd.812022-01-262025-08-20
A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer
SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab, Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin, Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin - Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer
Phase 3UnknownSuzhou Suncadia Biopharmaceuticals Co., Ltd.5612021-12-302021-11-24

Conditions studied

Uterine Cervical Neoplasms (1)

Sponsors

Suzhou Suncadia Biopharmaceuticals Co., Ltd. (3)

Countries

China (2)

Results publications

PMID 35653122